RYLD Among Covered Calls ETFs
End-of-day Nov 16, 2026 · 70 Covered calls ETFs by YTD
| Returns | Today | 1W | 1M | 3M | YTD | 1Y | 3Y | 5Y | Max |
|---|---|---|---|---|---|---|---|---|---|
| Total return | −0.6% | −0.7% | +2.0% | −3.8% | +10.8% | +13.8% | +34.6% | +9.5% | +48.8% |
| Peer average | −2.0% | −2.9% | −4.6% | −5.2% | +3.0% | +4.3% | +42.3% | +50.9% | — |
| S&P 500 · VOO | −1.9% | −1.7% | −3.0% | −3.3% | +9.4% | +11.3% | +77.3% | +69.2% | — |
$1015 of every $1,000 in RYLD is Global
| # | Ticker | Company | Weight ▼ |
|---|---|---|---|
| 1 | RSSL | Global X Russell 2000 ETF | 101.45% |
| # | ||||||
|---|---|---|---|---|---|---|
| 1 | RSSLGlobal X Russell 2000 ETF | Financial Services | 101.45% | $10,145.42 | 12.0M | $1.30B |
| 2 | —Cash | — | 0.12% | $11.98 | 1.5M | $1.5M |
| 3 | —Inhibrx | — | 0.00% | $0.08 | 16K | $10K |
| 4 | —Novartis AG - CVR | — | 0.00% | $0.08 | 26K | $10K |
| 5 | —Cartesian Therapeutics | — | 0.00% | $0.00 | 1 | $0 |
| 6 | RAINRAIN Oncology | Industrials | 0.00% | $0.00 | 1 | $0 |
| 7 | —Omniab - 15.00 Earnout | — | 0.00% | $0.00 | 2,421 | $0 |
| 8 | —Omniab - 12.5 Earnout | — | 0.00% | $0.00 | 2,421 | $0 |
| 9 | —Other Payable & Receivables | — | −0.02% | −$1.85 | -238K | −$238K |
| 10 | —RUT US 11/20/26 C2765 | — | −1.56% | −$155.70 | -4,647 | −$20.0M |
of the $42.3B in 90 Covered calls ETFs
Estimated yearly cost excludes trading costs and assumes constant assets.
| Ex-date | Paid | Per share |
|---|---|---|
| Oct 19, 2026 | Oct 22, 2026 | $0.15 |
| Sep 21, 2026 | Sep 24, 2026 | $0.15 |
| Aug 24, 2026 | Aug 27, 2026 | $0.17 |
| Jul 20, 2026 | Jul 23, 2026 | $0.16 |
| Jun 22, 2026 | Jun 25, 2026 | $0.16 |
| May 18, 2026 | May 21, 2026 | $0.16 |
| Apr 20, 2026 | Apr 23, 2026 | $0.16 |
| Mar 23, 2026 | Mar 26, 2026 | $0.15 |
| Feb 23, 2026 | Feb 26, 2026 | $0.16 |
| Jan 20, 2026 | Jan 23, 2026 | $0.16 |
| Dec 22, 2025 | Dec 30, 2025 | $0.16 |
| Nov 24, 2025 | Dec 2, 2025 | $0.15 |